Ductal carcinoma in situ (DCIS) presenting as a cystic retroareolar lesion in an African American man.

Ductal carcinoma in situ (DCIS) in males is rare, and there are limited data aimed at understanding the adequate workup, imaging, and follow-up for men who present with breast masses. Attention should be given to black men who have a higher cancer risk and worse prognosis than white male counterparts.

The lateral arm device for mammographic breast procedures: overview of its uses, safety, and efficacy.

Introduction: Percutaneous image-guided biopsy is the procedure of choice for diagnosing suspicious abnormalities on breast imaging. Stereotactic, ultrasound, and magnetic resonance imaging are used for image-guided breast biopsies. Stereotactic guidance uses mammography to localize lesions and facilitate placement of a core biopsy needle. The first systems used a vertical-approach needle insertion. The lateral arm device, which is the most recent advancement in stereotactic biopsies and pre-surgical localization allows procedures to be performed using a needle insertion parallel to the compression plate.Areas covered: The lateral arm device was introduced to the market in 2007 and is the first device of its kind. In this article we review the mechanism of this device, the risks and benefits of the device and other the different other modalities utilized to biopsy and localize the breast. We summarize the current literature on this device along with our own experiences utilizing this device.Expert opinion: The lateral arm device has changed the face of stereotactic-guided breast biopsies and localizations by allowing a new approach to perform these procedures. It has improved care to patients by allowing us to get to areas previously not within the biopsy window, decreased biopsy time and increased patient throughput.

Diagnostic Accuracy of Digital Breast Tomosynthesis in the Evaluation of Palpable Breast Abnormalities.

RATIONALE AND OBJECTIVES: The role of digital breast tomosynthesis (DBT) in evaluating palpable abnormalities has not been evaluated and its accuracy compared to 2D mammography is unknown. The purpose of this study was to evaluate combined 2D mammography, DBT, and ultrasound (US) at palpable sites. MATERIALS AND METHODS: Two breast imagers reviewed blinded consecutive cases with combined 2D mammograms and DBT examinations performed for palpable complaints. By consensus, 2D and DBT findings were recorded and compared to US. Patient characteristics, demographics, subsequent workup, and outcome were recorded. RESULTS: A total of 229 sites in 188 patients were included, with 50 biopsies performed identifying 18 cancers. All 18 cancers were identified on 2D and US, whereas 17 cancers were identified on DBT. Cancer detection sensitivities for 2D, DBT, and US were 100.0%, 94.4%, and 100.0%. The negative predictive value, when combined with US, was 100% for both. The sensitivity and the specificity for both benign and malignant findings with 2D and DBT were 70.5% versus 75.4% (P = 0.07) and 95.3% versus 99.1% (P = 0.125). Palpable findings not identified by 2D and DBT were smaller than those identified (11.5 ± 8.3 mm vs 23.9 ± 12.8 mm, P < 0.001). Patients with dense breasts were more likely to have mammographically occult findings than patients with nondense breasts (27.4% vs 8.3%). CONCLUSIONS: DBT did not improve cancer detection over 2D or US. Both mammographic modalities failed to identify sonographically confirmed findings primarily in dense breasts. The diagnostic use of DBT at palpable sites provided limited benefit over combined 2D and US. When utilizing DBT, US should be performed to adequately characterize palpable sites.